Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: A randomized controlled trial

JAMA

Volumn 296, Issue 19, 2006, Pages 2351-2361

  Marks, Leonard S ^a,b   Mazer, Norman A ^c   Mostaghel, Elahe ^h   Hess, David L ^d   Dorey, Frederick J ^e   Epstein, Jonathan I ^f   Veltri, Robert W ^f   Makarov, Danil V ^f   Partin, Alan W ^f   Bostwick, David G ^g   Macairan, Maria Luz ^b   Nelson, Peter S ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Urological Sciences Research Foundation   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g BOSTWICK LABORATORIES   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BIOLOGICAL MARKER; CD34 ANTIGEN; CLUSTERIN; KI 67 ANTIGEN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ENANTATE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SCREENING; TESTOSTERONE BLOOD LEVEL; URINE FLOW RATE;

EID: 33750978404     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.19.2351     Document Type: Article

References (54)

1. Liverman CT, Blazer DG. Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academy of Sciences; 2004.
2. Extent and nature of testosterone use [news release]. Fairfield, Conn: IMS Health; September 2006.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724-731.
4. Heller CG, Myers GB. The male climacteric: its symptomatology, diagnosis, and treatment. JAMA. 1944;126:472-477.
5. Hijazi RA, Cunningham GR. Andropause: is androgen replacement therapy indicated for the aging male? Annu Rev Med. 2005;56:117-137.
6. Morley JE, Perry HM III. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med. 2000;135:370-378.
7. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Eur Urol. 2005;48:1-4.
8. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839-2853.
9. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670-2677.
10. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469-3478.
11. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
12. Oesterling JE, Epstein JI, Walsh PC. The inability of adrenal androgens to stimulate the adult human prostate. J Urol. 1986;136:1030-1034.
13. Wu CP, Gu FL. The prostate in eunuchs. Prog Clin Biol Res. 1991;370:249-255.
14. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man. Science. 1974;186:1213-1215.
15. Huggins C, Stevens RA. The effect of castration on benign hypertrophy of the prostate in man. J Urol. 1940;43:705.
16. Huggins C, Stevens RA, Hodges CV. Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-223.
17. Johnson DE, Haynie TP. Phosphorus-32 for intractable pain in carcinoma of prostate. Urology. 1977;9:137-139.
18. Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126:372-375.
19. Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol. 1997;157:1845.
20. Schaeffer EM, Walsh PC. Risks of testosterone replacement. N Engl J Med. 2004;350:2004-2006.
21. Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. J Urol. 2005;174:534-538.
22. Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin Proc. 2000;75(suppl):S77-S81.
23. Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49:191-196.
24. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-1126.
25. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2257-2260.
26. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate. 2002;52:213-235.
27. Shirai T, Takahashi S, Cui L, et al. Experimental prostate carcinogenesis: rodent models. Mutat Res. 2000;462:219-226.
28. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men. J Androl. 2003;24:299-311.
29. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239-1242.
30. Marks LS, Partin AW, Gormley GJ, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol. 1997;157:2171-2178.
31. Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 2000;163:1451-1456.
32. Marks LS, Epstein JI, Partin AW. The role of prostate needle biopsy in evaluation of chemopreventive agents. Urology. 2001;57(suppl 1):191-193.
33. Marks LS, Hess DL, Dorey FJ, et al. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology. 2001;57:999-1005.
34. Resko JA, Ellinwood WE, Pasztor LM, Huhl AE. Sex steroids in the umbilical circulation of fetal rhesus monkeys from the time of gonadal differentiation. J Clin Endocrinol Metab. 1980;50:900-905.
35. Marks LS, Kojima M, Demarzo A, et al. Prostate cancer in native Japanese and Japanese-American men. Urology. 2004;64:765-771.
36. Nelson PS, Pritchard C, Abbott D, Clegg N. The human (PEDB) and mouse (mPEDB) Prostate Expression Databases. Nucleic Acids Res. 2002;30:218-220.
37. Pritchard CC, Hsu L, Delrow J, Nelson PS. Project normal: defining normal variance in mouse gene expression. Proc Natl Acad Sci U S A. 2001;98:13266-13271.
38. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
39. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. Cell. 2005;122:751-762.
40. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172-E1181.
41. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer. J Urol. 2003;170:2348-2351.
42. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167:2435-2439.
43. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
44. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505-508.
45. Mohler JL, Gaston KE, Moore DT, et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004;171:2277-2280.
46. Walsh PC, Hutchins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. J Clin Invest. 1983;72:1772-1777.
47. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:461-475.
48. Karr JP, Kim U, Resko JA, et al. Induction of benign prostatic hypertrophy in baboons. Urology. 1984;23:276-289.
49. Udayakumar TS, Tyagi A, Rajalakshmi M, et al. Changes in structure and functions of prostate by long-term administration of an androgen, testosterone enanthate, in rhesus monkey (Macaca mulatta). Anat Rec. 1998;252:637-645.
50. Kamischke A, Weinbauer GF, Semjonow A, Lerchl A, Richter KD, Nieschlag E. Estradiol and high-dose dihydrotestosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone. J Androl. 1999;20:601-610.
51. Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN, Wolfe RR. Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med. 2001;29:1936-1942.
52. Amory JK, Chansky HA, Chansky KL, et al. Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery. J Am Geriatr Soc. 2002;50:1698-1701.
53. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843-850.
54. Schroeder ET, Zheng L, Ong MD, et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab. 2004;89:4863-4872.